A detailed history of Pdt Partners, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Pdt Partners, LLC holds 14,900 shares of NBIX stock, worth $1.75 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
14,900
Holding current value
$1.75 Million
% of portfolio
0.17%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$114.58 - $153.15 $1.71 Million - $2.28 Million
14,900 New
14,900 $1.72 Million
Q3 2023

Nov 14, 2023

SELL
$94.02 - $117.1 $113,388 - $141,222
-1,206 Reduced 11.47%
9,306 $1.05 Million
Q2 2023

Aug 14, 2023

BUY
$89.53 - $104.87 $941,139 - $1.1 Million
10,512 New
10,512 $991,000
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $759,707 - $889,971
8,255 New
8,255 $877,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.2B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.